AMT 061

Uniqure NV (NASDAQ: QURE), a gene therapy company that focuses on severe unmet medical needs, could "dominate" the space with its AMT-061 therapy, according to B. Riley FBR. The Analyst B. Riley FBR's Madhu Kumar initiated coverage of Uniqure with a Buy rating and $50 price target....